Charcot neuro-osteoarthropathy (CNO), often called the Charcot foot, is one of the most serious and least recognized complications of diabetes. It is a progressive condition in which bones, joints, and soft tissues in the insensate foot break down, sometimes leading to profound deformity, ulceration, and in the worst cases, amputation. Because its earliest signs mimic more common problems, the window for effective intervention is frequently missed. Understanding how CNO presents, how it is diagnosed, and how it is managed is central to protecting limbs in people living with diabetes and peripheral neuropathy.
What Is the Charcot Foot?
CNO develops in a foot that has lost protective sensation, almost always due to diabetic peripheral neuropathy. The prevailing model of pathogenesis holds that repetitive, unnoticed trauma combines with a self-perpetuating inflammatory response. Pro-inflammatory signaling drives increased bone resorption, weakening the skeleton so that ordinary weight-bearing forces cause fractures, dislocations, and collapse of the arch. Because the foot is numb, the person often continues to walk on it, accelerating the destruction. A comprehensive 2024 review of the pathogenesis of acute diabetic Charcot arthropathy emphasizes that this interplay of neuropathy, unrecognized injury, and inflammation is what distinguishes CNO from ordinary fracture healing.
Why Early Recognition Is So Difficult
The acute Charcot foot typically presents as a warm, red, and swollen foot, frequently without significant pain because of the underlying neuropathy. These features are easily mistaken for cellulitis, deep vein thrombosis, gout, or osteomyelitis, and misdiagnosis is common. A practical clue is the temperature difference between the two feet: the affected foot is often several degrees warmer than the unaffected side.
The Role of Imaging
In the earliest phase, sometimes called Stage 0, plain X-rays can appear completely normal even while active destruction is under way. Magnetic resonance imaging (MRI) is far more sensitive at this stage, revealing bone marrow edema, microfractures, and joint changes before they are visible on radiographs. A 2025 narrative review on the radiological assessment of CNO underscores that advanced imaging is essential when clinical suspicion is high but X-rays are unremarkable, and that imaging should be interpreted alongside the clinical picture to exclude infection.
Current Standards of Diagnosis and Treatment
In 2023, the International Working Group on the Diabetic Foot (IWGDF) published its first dedicated guideline on active CNO, offering 26 recommendations across four areas: diagnosis, identification of remission, treatment, and prevention of re-activation. The guideline advises that a diagnosis of active CNO be made on clinical grounds, supported by imaging, and that other causes of a hot, swollen foot be excluded.
Offloading and Immobilization
The cornerstone of treatment during the active phase is immediate immobilization and offloading. A non-removable, knee-high offloading device, with the total contact cast regarded as the reference standard, is used to protect the foot from further mechanical stress while inflammation settles and the bones consolidate. This process typically takes many months, and premature return to unprotected weight-bearing risks renewed collapse. Reviews of offloading interventions for CNO consistently identify immobilization as the single most important step in preventing deformity and subsequent ulceration.
Monitoring for Remission
Deciding when the Charcot process has quieted is a clinical judgment supported by objective measures. The IWGDF guideline includes conditional recommendations for using infrared skin thermometry to monitor disease activity and help identify remission, since it is safe, inexpensive, and easy to perform. Studies cited in support of this approach found that the site of maximum temperature difference between the feet corresponded with radiographic findings in the large majority of cases, and that a temperature difference falling below roughly 2°C (about 4°F), together with clinical and imaging findings, can help signal that the foot is entering remission.
Key Takeaways
Charcot neuro-osteoarthropathy is a limb-threatening complication that hides behind ordinary-looking symptoms. A warm, swollen, often painless foot in a person with diabetic neuropathy should raise suspicion of active CNO until proven otherwise, even when X-rays look normal. Early diagnosis supported by MRI, prompt and sustained offloading in a non-removable device, and objective monitoring, including skin temperature comparison, together offer the best chance of halting bone destruction before irreversible deformity develops. Because misdiagnosis and delay are the principal drivers of poor outcomes, awareness of this condition among patients, caregivers, and clinicians remains one of the most valuable safeguards for the diabetic foot.
References
Wukich DK, Raspovic KM, Hobizal KB, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2024.
Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024.
Radiological Assessment of Charcot Neuro-Osteoarthropathy in the Diabetic Foot: A Narrative Review. Diagnostics. 2025;15(6):767.
Pathogenesis of Acute Diabetic Charcot Arthropathy in the Foot and Ankle: A Comprehensive Literature Review. Orthopedic Reviews. 2024.
Reviewing Recommendations From the IWGDF 2023 Guidelines on the Diagnosis and Treatment of Active Charcot Neuro-Osteoarthropathy: Highlighting the Role of Temperature Monitoring. Wounds. 2024.
Comments
